US2017112838A1PendingUtilityA1

Use of pemirolast

42
Assignee: RSPR PHARMA ABPriority: Oct 23, 2015Filed: Aug 12, 2016Published: Apr 27, 2017
Est. expiryOct 23, 2035(~9.2 yrs left)· nominal 20-yr term from priority
Inventors:Johan RaudCarl-Johan DalsgaardGöran Tornling
A61K 31/519A61K 45/06C07D 487/04
42
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

According to the invention there is provided a method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. Suitable lower doses of pemirolast are least about 110 mg per day.

Claims

exact text as granted — not AI-modified
1 . A method for the treatment of airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. 
     
     
         2 . A method as claimed in  claim 1 , wherein the dose of pemirolast (calculated as the free acid) is at least about 110 mg per day. 
     
     
         3 . A method as claimed in  claim 1 , wherein the dose of pemirolast (calculated as the free acid) is at least about 350 mg per day. 
     
     
         4 . A method as claimed in  claim 1 , wherein the treatment is of airway hyperresponsiveness in asthma patients. 
     
     
         5 . A method as claimed in  claim 4  wherein the dose of pemirolast (calculated as the free acid) is at least about 110 mg per day. 
     
     
         6 . A method as claimed in  claim 4 , wherein the dose of pemirolast (calculated as the free acid) is at least about 350 mg per day. 
     
     
         7 . A method as claimed in  claim 1 , wherein the patient is already receiving asthma treatment. 
     
     
         8 . A method as claimed in  claim 7 , wherein the dose of pemirolast (calculated as the free acid) is at least about 110 mg per day. 
     
     
         9 . A method as claimed in  claim 7 , wherein the dose of pemirolast (calculated as the free acid) is at least about 350 mg per day. 
     
     
         10 . A method for reducing airway hyperresponsiveness, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment. 
     
     
         11 . A method for the treatment of curative, non-symptomatic treatment of asthma, which method comprises the administration of pemirolast, or a pharmaceutically acceptable salt thereof, to a patient in need of such treatment.

Join the waitlist — get patent alerts

Track US2017112838A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.